Global drug sales are expected to climb steadily between 2024 and 2030, reaching $1.54 trillion in 2026 and $2.12 trillion by the end of 2030, according to GlobalData's pharmaceuticals database. So the demand for drugs is rising globally, especially for sophisticated drugs like anesthetics and cancer treatments. However, patients' access to necessary treatments is being hampered by ongoing drug shortages. Increased demand, supply chain interruptions, a lack of active pharmaceutical ingredients (APIs), and manufacturing problems are some of the factors causing these shortages. A robust and sustainable pharmaceutical supply chain is necessary to meet these difficulties. The industry can lower risks and increase supply reliability by streamlining manufacturing procedures, decreasing dependency on limited APIs, and improving delivery networks. Complex medications, such as gene and cell therapies, present particular difficulties because of their limited shelf lives and strict temperature requirements. Strong cold chain capabilities and backup plans are required by these variables. These difficulties are made worse by the complex production procedures and several locations that make up the pharmaceutical supply chain. [1]
According to the American Society of Health-System Pharmacists (ASHP), drug shortages in the US hit a record level in 2024. In the first quarter of 2024, ASHP reported a record 323 medicine shortages, exceeding the previous high of 320 in 2014. The anticipated August 2024 insulin replenishment has not yet occurred. There are backorders for a few Novo Nordisk medications, such as Ozempic, Novolin R Flexpens, and Novolog 10 mL vials. Back in 2023, within the US various reasons for shortage been reported by manufacturers during a University of Utah Drug Information Service (UUDIS) investigation. [2]
The sourcing of APIs is one aspect of the complicated and opaque global pharmaceutical supply chain. China, the biggest producer of APIs worldwide, is important, particularly for India, a big producer of generic medications. However, attempts to guarantee a consistent and sustainable supply of medications are hampered by the supply chain's lack of transparency. Because of confidentiality considerations, regulatory bodies are not allowed to share the information they have regarding API sources. Countries capacity to foresee and lessen supply chain disruptions, as those that occurred during the COVID-19 epidemic was hampered by this lack of public awareness. More openness is essential to solving this problem. Countries can better understand the supply chain loop holes and take proactive steps to secure important medications by carefully disclosing information on API sources, manufacturers of finished products, and marketers. New Zealand has shown practically that by applying transparency strategy can improve public health outcomes and supply chain resilience. [3]
At the moment, the best way to lower carbon emissions in the aviation sector is to use sustainable aviation fuel (SAF). SAF can assist the logistics sector, which includes the pharmaceutical industry, in reaching its sustainability objectives by drastically lowering carbon emissions. For supply chains to be optimized, pharmaceutical businesses and logistics providers must work together. Together, they can recognize and resolve logistical issues like product integrity and temperature management. Innovative solutions, such as eco-friendly packaging and effective procurement procedures, can be implemented via more cooperative approachRead More
(All Rights Reserved)